📋 Key Information Summary
- ADPKD is the most common inherited kidney disease (prevalence ~1:1,000–4,000), caused by pathogenic variants in PKD1 (~78%) or PKD2 (~15%); PKD1 mutations cause more severe disease with ESRF median age 54 v 74 years for PKD2.
- ARPKD is far rarer (~1:20,000–40,000), caused by biallelic PKHD1 mutations, typically presents in utero or in infancy with enlarged kidneys and congenital hepatic fibrosis.
- Diagnosis of ADPKD in at-risk adults (18–39 y): ≥3 unilateral or bilateral renal cysts on ultrasound (Ravine criteria revised by Pei); total kidney volume (TKV) on MRI is the best predictor of progression.
- Extrarenal manifestations include hepatic cysts (83%), intracranial aneurysms (5–10%), mitral valve prolapse (25%), and colonic diverticular disease.
- Target blood pressure <130/80 mmHg for all ADPKD patients; ACE inhibitors or ARBs are first-line antihypertensives.
- Tolvaptan (Jinarc®) slows cyst growth and eGFR decline in rapidly progressive ADPKD; PBS Authority Required listing in Australia with specific criteria.
- Screen for intracranial aneurysm with MRA if family history of SAH or aneurysm, or high-risk occupation; do not routinely screen asymptomatic low-risk patients.
- ~50% of ADPKD patients develop ESRF requiring RRT; causes ~10% of prevalent dialysis and ~6% of kidney transplant recipients in Australia.
- Manage volume status with adequate hydration (≥2.5–3 L/day); avoid excessive sodium intake (<6 g NaCl/day); counsel against nephrotoxic exposures.
- Aboriginal and Torres Strait Islander Australians have later presentation and reduced access to specialist nephrology care and pre-emptive transplantation.
- Genetic counselling is essential for all families; pre-symptomatic screening of at-risk children raises ethical considerations (no disease-modifying therapy for paediatric ADPKD).
- ADPKD accounts for 5–10% of the Australian dialysis population (~1,200 patients); median age at ESRF 54 years for PKD1, 74 years for PKD2.
Introduction & Australian Epidemiology
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease worldwide, caused predominantly by pathogenic variants in PKD1 (chromosome 16p13.3, encoding polycystin-1) and PKD2 (chromosome 4q21, encoding polycystin-2). It is characterised by the progressive bilateral development and growth of renal cysts, leading to a gradual decline in kidney function and eventual end-stage renal failure (ESRF) in approximately 50% of affected individuals.
In Australia, ADPKD affects an estimated 1 in 1,000 to 4,000 persons, with prevalence among the dialysis population of approximately 5–10% according to the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). At any given time, approximately 1,200 Australians with ADPKD are receiving dialysis or are living with a kidney transplant. The disease imposes significant morbidity, healthcare costs, and psychosocial burden on patients and families across all Australian jurisdictions.
Autosomal recessive polycystic kidney disease (ARPKD) is far rarer, with an estimated incidence of 1:20,000 to 40,000 live births. ARPKD is caused by biallelic mutations in PKHD1 (chromosome 6p12.2, encoding fibrocystin/polyductin) and typically presents antenatally or in early childhood with massively enlarged, echogenic kidneys and congenital hepatic fibrosis.
This guideline addresses both ADPKD and ARPKD, covering genetics, clinical features, extrarenal manifestations, diagnostic investigations, and contemporary management including disease-modifying therapy, blood pressure optimisation, and preparation for renal replacement therapy (RRT).
Genetics: ADPKD vs ARPKD
ADPKD — Autosomal Dominant Inheritance
ADPKD follows autosomal dominant inheritance with near-complete penetrance by age 80. Two major genes account for >90% of cases:
- PKD1 (~78% of families) — encodes polycystin-1, a large transmembrane receptor involved in cell–cell and cell–matrix signalling. PKD1 mutations produce more severe disease: median age at ESRF 54 years.
- PKD2 (~15% of families) — encodes polycystin-2, a non-selective cation channel. PKD2 mutations produce milder disease: median age at ESRF 74 years.
- A minority (~7%) have no identifiable mutation on conventional sequencing; deep intronic variants and mosaic mutations are increasingly recognised.
Genotype–phenotype correlation: PKD1 truncating mutations confer the worst prognosis (ESRF ~51 years), PKD1 non-truncating intermediate (~56 years), and PKD2 the mildest (~74 years). This stratification supports clinical trial enrichment and prognostic counselling.
ARPKD — Autosomal Recessive Inheritance
ARPKD is caused by biallelic pathogenic variants in PKHD1, encoding fibrocystin/polyductin. Key features:
- Both parents are obligate carriers (heterozygous); recurrence risk 25% per pregnancy.
- Carrier frequency ~1:70 in Caucasian populations; homozygous or compound heterozygous state leads to disease.
- Phenotypic spectrum ranges from perinatal lethality (Potter sequence) to presentation in adolescence with portal hypertension due to congenital hepatic fibrosis.
- Approximately 30% of affected neonates die in the perinatal period from pulmonary hypoplasia due to oligohydramnios.
| Feature | ADPKD | ARPKD |
|---|---|---|
| Inheritance | Autosomal dominant | Autosomal recessive |
| Gene | PKD1, PKD2 | PKHD1 |
| Prevalence | 1:1,000–4,000 | 1:20,000–40,000 |
| Typical age at dx | 30–50 years | In utero – infancy |
| Renal cysts | Macroscopic, bilateral, progressive | Microscopic, diffuse collecting-duct dilatation |
| Liver involvement | Simple hepatic cysts (83%) | Congenital hepatic fibrosis (caroli complex) |
| ESRF age (median) | 54 y (PKD1), 74 y (PKD2) | Variable; ~20–30% in childhood |
| Genetic testing | NGS panel / WES | PKHD1 sequencing |
Genetic Testing in Australia
Indications for genetic testing include: (1) atypical imaging (unilateral or asymmetric disease, early-onset, no family history); (2) potential living kidney donor evaluation; (3) reproductive counselling; and (4) paediatric presentations. Testing is available through accredited laboratories in all Australian states (e.g., Victorian Clinical Genetics Services, SA Pathology, PathWest). Costs may be partially offset by Medicare under MBS item 73309 (familial mutation testing) when a known family variant exists. Panel-based next-generation sequencing (NGS) for PKD1/PKD2 costs approximately AUD 500–800 in the private setting.
Clinical Features & Extrarenal Manifestations
Renal Manifestations
- Renal enlargement: Progressive bilateral kidney enlargement detectable by palpation in ~60% of patients by age 40. Total kidney volume (TKV) is the strongest predictor of future GFR decline.
- Flank or abdominal pain: Most common presenting symptom (~60%); due to cyst enlargement, haemorrhage into a cyst, or nephrolithiasis.
- Haematuria: Gross or microscopic; may follow trauma, exercise, or spontaneous cyst rupture.
- Nephrolithiasis: Affects 20–30%; uric acid (57%) and calcium oxalate stones; metabolic workup recommended.
- Urinary tract infections and cyst infections: Increased susceptibility; cyst infection is notoriously difficult to treat (poor drug penetration).
- Hypertension: Present in >60% before any measurable GFR decline; driven by intrarenal activation of the RAAS system.
- ESRF: Develops in ~50%; median age 54 y (PKD1) to 74 y (PKD2).
Extrarenal Manifestations
Hepatic Cysts
Most common extrarenal manifestation
Prevalence83% of patients by age 30
Clinical significanceUsually asymptomatic; massive hepatomegaly in women (oestrogen-driven)
ManagementSurveillance US if symptomatic; somatostatin analogues or surgical fenestration
Intracranial Aneurysm (ICA)
Affects 5–10% of ADPKD patients
Risk factorsFamily history of ICA or SAH, previous ICA, autosomal dominant PKD with coexisting HTN
ScreeningMRA every 5 y if family history; do not routinely screen low-risk patients
OutcomeAnnual rupture risk ~0.5–1% for unruptured aneurysms <7 mm
Cardiac Manifestations
Mitral valve prolapse, aortic root dilation
MVP prevalence~25% of ADPKD patients
ManagementEchocardiography if murmur; endocarditis prophylaxis no longer standard
Colonic Diverticular Disease
Increased prevalence in ADPKD
PrevalenceHigher than age-matched controls, especially on dialysis
Clinical significancePeritonitis risk pre-transplant; bowel prep consideration
ARPKD-Specific Features
- Massively enlarged, echogenic kidneys bilaterally on antenatal ultrasound.
- Pulmonary hypoplasia secondary to oligohydramnios — leading cause of perinatal death (~30%).
- Congenital hepatic fibrosis and Caroli disease — portal hypertension, cholangitis, varices.
- Hypertension in >80% of survivors; requires aggressive antihypertensive therapy.
Investigations (Ultrasound, MRI, Genetics)
Imaging Criteria for ADPKD Diagnosis
| Age (years) | Positive diagnosis criteria (ultrasound) | Negative to exclude ADPKD |
|---|---|---|
| 15–39 | ≥3 cysts, unilateral or bilateral | <3 cysts (high negative predictive value) |
| 40–59 | ≥2 cysts in each kidney | <2 cysts in each kidney |
| ≥60 | ≥4 cysts in each kidney | <4 cysts in each kidney (less reliable) |
These revised unified criteria (Pei et al., 2009, 2015) supersede the older Ravine criteria and improve sensitivity for PKD2 carriers. They assume a known family history of ADPKD and the absence of other cystic diseases.
Available
Renal Ultrasound
First-line screening modality. MBS item 55032 (kidney ultrasound). Detects cysts ≥1 cm; limited sensitivity for small cysts in young adults. Repeat at age 18 for at-risk relatives. Available at all Australian public and private radiology facilities.
Available
MRI — Total Kidney Volume (TKV)
Gold standard for TKV measurement using ellipsoid or semi-automated segmentation. TKV >750 mL or height-adjusted TKV (htTKV) >600 mL/m is classified as rapidly progressive (Mayo Class 1C–1E). Essential for Tolvaptan eligibility assessment. MBS item 63454 (MRI abdomen, renal). Requires nephrology referral for public funding.
Available
CT Abdomen
Useful for nephrolithiasis characterisation or pre-surgical planning. Lower sensitivity for small cysts than MRI. MBS item 56800. Avoid if possible due to radiation and contrast risks.
Specialist
MRA Brain (Screening for ICA)
Non-contrast MRA preferred for intracranial aneurysm screening. MBS item 63057 (MRA head). Indicated if: family history of ICA/SAH, prior ICA, planned major surgery, high-risk occupation (e.g., pilot), or patient anxiety with informed discussion. Repeat every 5 years if negative.
Specialist
Genetic Testing (NGS Panel)
PKD1/PKD2 panel sequencing. Indicated for atypical imaging, living donor evaluation, reproductive counselling, or paediatric presentations. Cost ~AUD 500–800 (private); Medicare rebate available for familial mutation testing (MBS 73309). VCGS (Melbourne), SA Pathology (Adelaide), PathWest (Perth).
Available
Renal Function (eGFR, UACR)
eGFR (CKD-EPI 2021) and urine ACR for CKD staging. Baseline and at least annual monitoring. MBS item 66551 (eGFR), 66512 (albumin–creatinine ratio).
Prognostic Classification (Mayo Classification)
The Mayo Clinic classification stratifies ADPKD patients into five height-adjusted TKV (htTKV) classes based on age and kidney volume, predicting the rate of GFR decline:
Slow
Class 1A–1B
htTKV below or near expected for age. Minimal cyst burden. eGFR decline <1 mL/min/year.
ESRF unlikely before age 70–80
Intermediate
Class 1C
htTKV mildly elevated for age. Moderate cyst burden. eGFR decline ~1.5–2 mL/min/year.
ESRF expected age 60–70
Rapid
Class 1D–1E
htTKV significantly elevated. Massive kidneys. eGFR decline >3–5 mL/min/year.
ESRF expected age 45–55; Tolvaptan eligible
Management (Tolvaptan, Blood Pressure, ESRF)
Blood Pressure Management
Hypertension is present in >60% of ADPKD patients before any measurable GFR decline and is associated with faster progression to ESRF, left ventricular hypertrophy, and increased cardiovascular risk.
- Target: <130/80 mmHg for all ADPKD patients (KDIGO 2024, RACGP).
- First-line: ACE inhibitor (e.g., ramipril) or ARB (e.g., telmisartan) — preferred over calcium channel blockers due to superior renoprotective effects and evidence from the HALT-PKD trial.
- Combine with non-dihydropyridine CCB (diltiazem) or diuretic as second-line if target not achieved.
- Avoid excessive diuresis — maintain high fluid intake (≥2.5–3 L/day) to suppress vasopressin-mediated cyst growth.
Ramipril
Tritace® · Generic · ACE inhibitor
Adult dose2.5–10 mg PO daily; start 2.5 mg and titrate
Paediatric dose0.1–0.5 mg/kg/day PO (max 10 mg); avoid in children <6 years
Renal adjustmentStart 1.25 mg if eGFR <30 mL/min; monitor K⁺ and creatinine closely
PBS status✔ PBS General Benefit
Telmisartan
Micardis® · ARB
Adult dose20–80 mg PO daily
Renal adjustmentNo dose change; monitor K⁺
PBS status✔ PBS General Benefit
HALT-PKD Study A findings: In early-stage ADPKD (eGFR >60 mL/min), combination ACEi+ARB therapy did not demonstrate additional benefit over ACEi monotherapy and was associated with more adverse events (hyperkalaemia, hypotension). ACEi or ARB monotherapy is recommended; avoid dual RAAS blockade.
Tolvaptan — Disease-Modifying Therapy
Tolvaptan (Jinarc®) is a selective vasopressin V2 receptor antagonist that reduces cAMP-driven cyst proliferation and fluid secretion. The TEMPO 3:4 trial demonstrated a 49% reduction in the rate of TKV growth and a 26% reduction in eGFR decline over 3 years. The REPRISE trial confirmed benefit in later-stage ADPKD (eGFR 25–65 mL/min).
Tolvaptan
Jinarc® · V2 receptor antagonist
Adult dose45/15 mg PO daily (split dose AM/PM); titrate from 15/15 → 30/15 → 45/15 mg over 4 weeks
Paediatric doseNot established; not PBS-listed for paediatric use in Australia
RouteOral
Renal adjustmentNo dose adjustment for eGFR; stop if eGFR <10 mL/min
Hepatic adjustmentContraindicated in significant liver disease; monitor LFTs
Key ADRsAquaresis (polyuria, polydipsia, nocturia — nearly universal); hepatotoxicity (LFT monitoring required); hypernatraemia
PBS status⚠ PBS Authority Required
PBS criteriaRapidly progressive ADPKD (Mayo Class 1C–1E) with eGFR 25–65 mL/min; initiation by nephrologist; prior approval through Services Australia (PBS item 12324Y)
MonitoringLFTs at baseline, then monthly ×18 months, then every 3 months. Sodium at 1 week, 2 weeks, then monthly.
Hepatotoxicity risk: Tolvaptan has been associated with clinically significant liver injury, including cases requiring liver transplantation. LFTs must be monitored as per the schedule above. Discontinue permanently if ALT >3× ULN with symptoms or ALT >5× ULN regardless of symptoms. Ensure patients understand the need for fluid access throughout the day and night.
Supportive & Preventive Measures
| Measure | Recommendation | Evidence basis |
|---|---|---|
| Fluid intake | ≥2.5–3 L water per day (suppress vasopressin) | Observational; supported by TEMPO rationale |
| Sodium restriction | <6 g NaCl/day (100 mmol Na⁺) | HALT-PKD; reduces HTN and proteinuria |
| Avoid nephrotoxins | Minimise NSAIDs, IV contrast (hydrate if necessary), aminoglycosides | General CKD principles; KDIGO |
| Weight management | BMI 18.5–25 kg/m² | Observational; slower GFR decline |
| Exercise | Regular moderate activity; avoid contact sports (risk of cyst rupture/haemorrhage) | Expert consensus |
| Pregnancy | Safe in most; stop tolvaptan before conception (teratogenicity risk); monitor HTN closely | FDA pregnancy category X (tolvaptan) |
Management of ESRF & Renal Replacement Therapy
Approximately 50% of ADPKD patients will develop ESRF. Preparation for RRT should begin when eGFR falls below 20–25 mL/min.
1
Pre-emptive Transplantation
The preferred RRT option for suitable candidates. Live donor kidney transplant is ideal — living unrelated donors (spouse, partner) are acceptable. ADPKD kidneys are not auto-transplanted. Bilateral native nephrectomy may be performed pre- or peri-transplant if kidneys are massively enlarged (>1.5 kg each) to create space.
2
Dialysis Initiation
Haemodialysis or peritoneal dialysis. AV fistula creation should be planned when eGFR <20 mL/min. PD catheter insertion timing: allow 2–4 weeks before use. Massive kidneys may reduce peritoneal cavity space — assess suitability for PD on imaging.
3
Transplantation
Kidney transplant alone (not combined liver–kidney for ADPKD hepatic cysts). Patient survival at 5 years ~90%. ANZDATA reports ~6% of Australian kidney transplant recipients have ADPKD. Immunosuppression: standard protocol (tacrolimus + mycophenolate ± corticosteroids).
Management of Cyst Complications
- Cyst infection: Fluoroquinolones (ciprofloxacin 500–750 mg PO BD) are first-line due to superior cyst penetration. Treat for 4–6 weeks. If unresponsive: surgical or percutaneous drainage.
- Cyst haemorrhage: Usually self-limiting; conservative management, adequate hydration, avoid antiplatelet agents acutely.
- Nephrolithiasis: Metabolic workup (serum urate, calcium, citrate; 24-h urine). Treat with increased fluid intake, potassium citrate for hypocitraturia, and standard urological management.
- Chronic pain: Step-wise analgesic approach; avoid long-term NSAIDs. Consider cyst aspiration with sclerotherapy, surgical cyst decortication, or rarely nephrectomy.
Special Populations
Pregnancy
Tolvaptan: Contraindicated — stop ≥4 weeks before planned conception. Category X (teratogenic in animal studies).
ACEi/ARBs: Contraindicated in 2nd and 3rd trimesters (fetotoxicity). Switch to labetalol, nifedipine, or methyldopa in early pregnancy.
HTN management: Target <135/85 mmHg (RANZCOG). Monitor for pre-eclampsia (more common in ADPKD with pre-existing HTN).
Most women with ADPKD and normal renal function have successful pregnancies. Increased UTI risk — screen urine regularly. Rare complications: rupture of hepatic cyst, hepatic haemorrhage.
Paediatric
ADPKD in children: Usually asymptomatic; incidental finding of cysts or HTN. Cyst development may occur in utero.
Monitoring: Blood pressure at every visit; annual renal ultrasound from age 5–10 if family history positive.
HTN treatment: ACEi preferred (ramipril 0.1–0.5 mg/kg/day). Target <90th percentile for age/height.
Tolvaptan: Not currently indicated or PBS-listed for paediatric ADPKD in Australia.
ARPKD: Aggressive neonatal respiratory support if pulmonary hypoplasia. Monitor for portal hypertension from childhood. Paediatric nephrologist and hepatologist co-management essential.
Ethical considerations: Pre-symptomatic genetic testing in children is controversial. Psychological support for families is recommended (PKD Australia).
Elderly
ADPKD patients who reach age >60 with preserved eGFR are likely PKD2 carriers or have milder phenotype — continue monitoring but tolvaptan unlikely to change trajectory.
Increased fall risk with aggressive antihypertensive therapy — individualise BP targets (<140/90 may be acceptable).
RRT suitability assessment should be individualised — consider conservative management for frail elderly patients.
Renal Impairment
eGFR 60–90: Full dose ACEi/ARB. Tolvaptan not indicated (slow-progressor phenotype).
eGFR 25–65: Tolvaptan eligible if rapidly progressive (Mayo 1C–1E). Start ACEi at lower dose. Avoid NSAids. Monitor electrolytes closely.
eGFR <25: Prepare for RRT. Tolvaptan may be continued until eGFR <10 then stop. Nephrology transition clinic referral.
Hepatic Impairment
Tolvaptan: Contraindicated in significant liver disease. Perform LFTs before initiation and at regular intervals.
Massive hepatic cysts: Consider somatostatin analogue (octreotide LAR 20 mg IM monthly, off-label), surgical fenestration, or liver transplantation in extreme cases.
Immunocompromised
Post-transplant immunosuppression increases infection risk — be vigilant for UTI, pyelonephritis, and cyst infections.
Standard transplant immunosuppression: tacrolimus + mycophenolate mofetil ± prednisolone.
CMV/EBV prophylaxis as per transplant unit protocol.
Aboriginal and Torres Strait Islander Health
Aboriginal and Torres Strait Islander Health Considerations
Key action: Engage local Aboriginal Health Workers and use culturally safe telehealth platforms for specialist nephrology review. Ensure language-appropriate educational materials are provided through local Aboriginal Community Controlled Health Organisations (ACCHOs).
📚 References
- 1. Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015;88(1):17–27.
- 2. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930–1942.
- 3. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–2418. (TEMPO 3:4)
- 4. Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255–2266. (HALT-PKD Study A)
- 5. Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205–212.
- 6. Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160–172.
- 7. The National ESKD Advisory Committee and Kidney Health Australia. Chronic Kidney Disease (CKD) Management in Primary Care. 4th edition. Melbourne: Kidney Health Australia; 2020.
- 8. AIHW. Chronic kidney disease in Aboriginal and Torres Strait Islander people. Cat. no. PHE 251. Canberra: Australian Institute of Health and Welfare; 2022.
- 9. ANZDATA Registry. 46th Annual Report 2023 (Data to 2022). Adelaide: Australia and New Zealand Dialysis and Transplant Registry.
- 10. KDIGO 2024 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314.
- 11. Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016;67(5):792–810.
- 12. Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4(1):50.
- 13. Horie S, Mochizuki T, Kaname S. Autosomal dominant polycystic kidney disease: pathogenesis, biomarkers, and treatment. Clin Exp Nephrol. 2022;26(7):623–634.
- 14. Services Australia. Pharmaceutical Benefits Schedule — Tolvaptan. PBS Item 12324Y. Canberra; 2024. Available from: pbs.gov.au.